glp 1 in obesity The Role of Glp-1 Receptor Agonists Insulin Resistance with Concomitant Treatment in Polycystic Ovary Syndrome What is the pipeline for

Other research highlights: 30% of GLP-1 users tested positive for SIBO or IMO even after accounting for diabetes (5) GLP-1 medicines caused microbiome changes and altered metabolism in mice (6) GLP-1 medicines tested in humans only had noticeable microbiome changes by 48 weeks (7) Despite not necessarily having slower gut motility, one study found that 88.9% of obese patients had SIBO (8) A meta analysis of people with IBS symptoms, found that up to 78% of people had SIBO, many of whom were undiagnosed (9) Overall, Sun and colleagues (1) could not prove a mechanistic link between GLP-1 medications and SIBO, however they did find that SIBO was twice as likely in GLP-1 users

Nausea, vomiting, diarrhea, and constipation occur in 2050% of patients, though symptoms are typically mild to moderate and diminish over time

Hussain A, Farzam K

Theyve also become popular through media coverage, and social media influencers and celebrities talking about their experiences taking the medications

Reduced caloric intake from appetite suppression can contribute to fatigue, as can the metabolic adjustments your body makes in response to GLP-1 receptor activation

Focusing on clinically guided lifestyle and nutrition programs, supplemented when appropriate with proven medical therapies, promotes long-term health while keeping spending in check